Idioma:

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Costa, Ricardo L. B. ; Han, Hyo Sook ; Gradishar, William J.

Breast cancer research and treatment, 2018-06, Vol.169 (3), p.397-406 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Autor: Costa, Ricardo L. B. ; Han, Hyo Sook ; Gradishar, William J.
Assuntos: 1-Phosphatidylinositol 3-kinase ; AKT protein ; Animals ; Biomarkers ; Breast cancer ; Cancer ; Cancer metastasis ; Cancer research ; Cancer treatment ; Care and treatment ; Clinical trials ; Drug delivery ; Drug development ; Epidermal growth factor ; Epidermal growth factors ; Female ; Gene Expression Regulation, Neoplastic - drug effects ; Genetic Variation ; Health aspects ; Humans ; Kinases ; MAP kinase ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Mitogens ; Molecular Targeted Therapy ; Oncology ; Paclitaxel ; Phosphatidylinositol 3-Kinase - metabolism ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Protein kinases ; Proto-Oncogene Proteins c-akt - metabolism ; Rapamycin ; Review ; Signal Transduction - drug effects ; TOR protein ; TOR Serine-Threonine Kinases - metabolism ; Toxicity ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - genetics ; Triple Negative Breast Neoplasms - metabolism ; Triple Negative Breast Neoplasms - pathology
É parte de: Breast cancer research and treatment, 2018-06, Vol.169 (3), p.397-406
Descrição: Purpose Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. Although there have been advances in the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancers, targeted therapies for TNBC remain unavailable. In this narrative review, we summarize recent discoveries related to the underlying biology of the phosphoinositide 3-kinase ( PI3K )/protein kinase B ( AKT )/mechanistic target of rapamycin ( mTOR ) pathway in TNBC, examine clinical progress to date, and suggest rational future approaches for investigational therapies in TNBC. Results As with other subtypes of breast cancer, aberrations in the PI3K/AKT/mTOR pathway are common in TNBC. Preclinical data support the notion that these aberrations predict TNBC inhibition by targeted agents. In a recently published phase 2 clinical trial, an AKT inhibitor (ipatasertib) improved outcomes in a subset of patients with metastatic TNBC when combined with paclitaxel in the first-line setting. In addition, new compounds with distinct specificity and potency targeting different PI3K/AKT/mTOR components and cognate molecules (e.g., mitogen-activated protein kinase) are being developed. These agents present a wide range of toxicity profiles and early efficacy signals, which must be considered prior to the advancement of new agents in later-phase clinical trials. Conclusions The development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways.
Editor: New York: Springer US
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 2 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Costa, Ricardo L. B. ; Han, Hyo Sook ; Gradishar, William J.

New York: Springer US

Buscando em bases de dados remotas. Favor aguardar.